NLRP3 and renal cell carcinoma: In addition, recent studies have shown that inhibition of BRD4 in RCC suppresses cell proliferation as well as epithelial–mesenchymal transition (EMT) progression and plays an anti-tumour role in renal cell carcinoma by activating the NF-κB-NLRP3-Caspase-1 signalling pathway [46].